Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 8, 2007, Pages 2184-2187

  Armstrong, Helen E ^a   Galka, Amy ^a   Lin, Linus S ^a   Lanza Jr , Thomas J ^a   Jewell, James P ^a   Shah, Shrenik K ^a   Guthikonda, Ravi ^a   Truong, Quang ^a   Chang, Linda L ^a   Quaker, Grace ^a   Colandrea, Vincent J ^a   Tong, Xinchun ^a   Wang, Junying ^a   Xu, Sherry ^a   Fong, Tung M ^a   Shen, Chun Pyn ^a   Lao, Julie ^a   Chen, Jing ^a   Shearman, Lauren P ^a   Stribling, D Sloan ^a   Rosko, Kimberly ^a   Strack, Alison ^a   Ha, Sookhee ^a   der Ploeg, Lex Van ^a   Goulet, Mark T ^a   Hagmann, William K ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cannabinoid; CB 1R; Obesity; Sulfonamide

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AMIDE; CANNABINOID RECEPTOR AGONIST; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HYPOTHERMIA; NONHUMAN; RAT;

ANIMALS; ANTI-OBESITY AGENTS; BRAIN CHEMISTRY; ENDOCANNABINOIDS; HUMANS; HYPOTHERMIA; INHIBITORY CONCENTRATION 50; PHARMACOKINETICS; RATS; RECEPTOR, CANNABINOID, CB1; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 33947577209     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.087     Document Type: Article

References (16)

1. Bray G.A. J. Med. Chem. 49 (2006) 4001
2. Antel J., Gregory P.C., and Nordheim U. J. Med. Chem. 49 (2006) 4008
3. Pertwee R. AAPS J. 7 (2005) E625
4. Muccioli G.G., and Lambert D.M. Curr. Med. Chem. 12 (2005) 1361
5. Le Foll B., and Goldberg S.R. J. Pharmacol. Exp. Ther. 312 (2005) 875
6. Gelfand E.V., and Cannon C.P. J. Am. Coll. Cardiol. 47 (2006) 1919
7. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Lancet 365 (2005) 1389
8. Drugs Future 30 (2005) 128
9. Lin L.S., Lanza T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Fong T.M., Shen C.-P., Lao J., Xiao J.C., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., Van der Ploeg L., Goulet M.T., and Hagmann W.H. J. Med. Chem. 49 (2006) 7584
10. The target sulfonamides were separated by chiral HPLC on a Chiralcel-OC 4.5 mm × 250 mm column eluted with ethanol/hexane to afford the individual enantiomers.
11. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., and Mitchell R.L. Mol. Pharmacol. 48 (1995) 443
12. The coordinates for the X-ray structure of MK-0364 have been deposited with the Cambridge Crystallographic Data Centre with the deposition number CCDC632855. An analysis of the X-ray and NMR structures and a conformational analysis will be the subject of a manuscript in preparation (Lin, L. S., et al.).
13. Pertwee R.G., Stevenson L.A., and Griffin G. Br. J. Pharmacol. 110 (1993) 1483
14. Hamill, T. G.; Lin, L. S.; Liu, P.; Jewell, J. P.; Goulet, M. T.; Hagmann, W. K.; Fong, T. M.; Hargreaves, R. J.; Burns, H. D. J. Labeled Compd. Radiopharm., (in press).
15. Burns, H. D.; Van Laere, K.; Sanabria-Bohorquez, S.; Hamill, T. G.; Bormans, G.; Eng, W.; Gibson, R. E.; Ryan, C.; Connolly, B. M.; Patel, S.; Krause S. M.; Van Hecken, A.; Dupont, P.; De Lepeleire, I.; Liu, P.; Jewell, J. P.; Lanza, T. J.; Lin, L. S.; Hagmann, W. K.; Goulet, M. G.; de Hoon, J.; Mortelmans, L.; Fong, T. M.; Hargreaves, R. Proc. Natl. Acad. Sci. U.S.A., (submitted for publication)
16. Liu, P.; Lin, L. S.; Hamill, T. G.; Jewell, J. P.; Lanza, T. J.; Gibson, R. E.; Krause, S. M.; Ryan, C.; Eng, W.; Sanabria, S.; Tong, X.; Wang, J.; Levorse, D. A.; Owens, K. A.; Fong, T. M.; Shen, C.; Lao, Z. J.; Kumar, S.; Yin, W.; Payack, J. F.; Springfield, S. A.; Hargreaves, R. J.; Burns, H. D.; Goulet, M.T.; Hagmann, W.K. (submitted for publication).